ChemicalBook > CAS DataBase List > Rinucumab
Rinucumab
- Product Name
- Rinucumab
- CAS No.
- 1569263-06-4
- Chemical Name
- Rinucumab
- Synonyms
- Rinucumab;Research Grade Rinucumab;Research Grade Rinucumab (DHC42201)
- CBNumber
- CB48080956
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Rinucumab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Rinucumab Chemical Properties,Usage,Production
Uses
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration[1].
References
[1] Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13(7):487. DOI:10.1038/nrd4375
Rinucumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Rinucumab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
1569263-06-4, RinucumabRelated Search:
Cendakimab
Bertilimumab
Tesnatilimab
Ivicentamab
Depatuxizumab
Ulenistamab
Pavunalimab
Siplizumab
Sotevtamab
Lorvotuzumab Mertansine